Both Sol-Gel Technologies Ltd. (NASDAQ:SLGL) and Evofem Biosciences Inc. (NASDAQ:EVFM) are each other’s competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sol-Gel Technologies Ltd.||8||25.29||N/A||-1.79||0.00|
|Evofem Biosciences Inc.||5||0.00||N/A||-3.08||0.00|
Table 1 demonstrates Sol-Gel Technologies Ltd. and Evofem Biosciences Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 has Sol-Gel Technologies Ltd. and Evofem Biosciences Inc.’s return on equity, return on assets and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Sol-Gel Technologies Ltd.||0.00%||0%||0%|
|Evofem Biosciences Inc.||0.00%||524.3%||-617.1%|
Institutional and Insider Ownership
Sol-Gel Technologies Ltd. and Evofem Biosciences Inc. has shares held by institutional investors as follows: 12.8% and 55.8%. About 79.39% of Sol-Gel Technologies Ltd.’s share are held by insiders. On the other hand, insiders held about 31.5% of Evofem Biosciences Inc.’s shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Sol-Gel Technologies Ltd.||0.69%||13.22%||40.75%||67.6%||48.98%||69.27%|
|Evofem Biosciences Inc.||-2.99%||-13.98%||23.98%||47.27%||117.94%||15.99%|
For the past year Sol-Gel Technologies Ltd. has stronger performance than Evofem Biosciences Inc.
On 6 of the 7 factors Sol-Gel Technologies Ltd. beats Evofem Biosciences Inc.
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.